
-
Vir Biotechnology NASDAQ:VIR Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting SARS-CoV-2, hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis.
Location: | Website: www.vir.bio | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
152.5M
Cash
905.3M
Avg Qtr Burn
-111.6M
Short % of Float
8.43%
Insider Ownership
12.01%
Institutional Own.
76.71%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tobevibart + Elebsiran Details Infectious disease, Hepatitis Delta Virus | Phase 3 Data readout | |
Sotrovimab VIR-7831 (GSK4182136) Details COVID-19, Infectious disease | Phase 3 Update | |
VIR-3434 +/- VIR-2218 +/- PEG-IFNα Details Infectious disease, Hepatitis B | Phase 2 Data readout | |
VIR-3434 + VIR-2218 Details Infectious disease, Hepatitis B | Phase 2 Data readout | |
VIR-2482 (Universal prophylaxis) Details Influenza, Infectious disease | Phase 2 Update | |
VIR-5818 + Pembrolizumab Details Cancer, HER2-expressing cancers, Metastatic breast cancer, Metastatic colorectal cancer | Phase 1 Data readout | |
VIR-5500 Details Cancer, Castration-resistant prostate cancer | Phase 1 Data readout | |
VIR-1388 (HVTN 142) Details Infectious disease, Human immunodeficiency virus, Vaccine | Phase 1 Data readout | |
VIR-5525 Details Cancer, Head and neck squamous cell carcinoma, Non-small cell lung carcinoma, Metastatic colorectal cancer | Phase 1 Initiation | |
Sotrovimab VIR-7831 (GSK4182136) Details COVID-19, Infectious disease | Failed Discontinued | |
VIR-1111 Details Infectious disease, Human immunodeficiency virus, Vaccine | Failed Discontinued |